Protalix BioTherapeutics, Inc. (PLX)
USD 2.24
(-6.28%)
USD 2.24
(-6.28%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.62 Million USD | -85.72% |
| 2022 | 32.35 Million USD | 0.29% |
| 2021 | 32.26 Million USD | 622.25% |
| 2020 | 4.46 Million USD | -91.95% |
| 2019 | 55.48 Million USD | 15.68% |
| 2018 | 47.96 Million USD | 3.67% |
| 2017 | 46.26 Million USD | 95.68% |
| 2016 | 23.64 Million USD | -67.21% |
| 2015 | 72.09 Million USD | 6.87% |
| 2014 | 67.46 Million USD | 0.62% |
| 2013 | 67.04 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 47.93 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.49 Million USD | 0.0% |
| 2024 Q2 | 4.28 Million USD | 0.0% |
| 2023 Q4 | 4.62 Million USD | 2.64% |
| 2023 FY | 4.62 Million USD | -85.72% |
| 2023 Q1 | 32.41 Million USD | 0.19% |
| 2023 Q2 | 24.7 Million USD | -23.78% |
| 2023 Q3 | 4.5 Million USD | -81.78% |
| 2022 Q4 | 32.35 Million USD | 0.67% |
| 2022 Q2 | 31.92 Million USD | -0.71% |
| 2022 Q3 | 32.14 Million USD | 0.68% |
| 2022 Q1 | 32.15 Million USD | -0.33% |
| 2022 FY | 32.35 Million USD | 0.29% |
| 2021 Q3 | 32.25 Million USD | 615.71% |
| 2021 Q1 | 4.31 Million USD | -3.31% |
| 2021 FY | 32.26 Million USD | 622.25% |
| 2021 Q4 | 32.26 Million USD | 0.02% |
| 2021 Q2 | 4.5 Million USD | 4.35% |
| 2020 Q4 | 4.46 Million USD | -92.31% |
| 2020 FY | 4.46 Million USD | -91.95% |
| 2020 Q1 | 56.25 Million USD | 1.39% |
| 2020 Q2 | 57.14 Million USD | 1.58% |
| 2020 Q3 | 58.06 Million USD | 1.6% |
| 2019 Q2 | 53.96 Million USD | 1.5% |
| 2019 Q3 | 54.69 Million USD | 1.35% |
| 2019 Q4 | 55.48 Million USD | 1.44% |
| 2019 Q1 | 53.16 Million USD | 10.85% |
| 2019 FY | 55.48 Million USD | 15.68% |
| 2018 Q3 | 47.32 Million USD | 1.24% |
| 2018 FY | 47.96 Million USD | 3.67% |
| 2018 Q4 | 47.96 Million USD | 1.37% |
| 2018 Q2 | 46.74 Million USD | 1.38% |
| 2018 Q1 | 46.1 Million USD | -0.34% |
| 2017 FY | 46.26 Million USD | 95.68% |
| 2017 Q3 | 57.92 Million USD | 0.08% |
| 2017 Q1 | 117.5 Million USD | 396.98% |
| 2017 Q4 | 46.26 Million USD | -20.13% |
| 2017 Q2 | 57.88 Million USD | -50.74% |
| 2016 FY | 23.64 Million USD | -67.21% |
| 2016 Q1 | 72.2 Million USD | 0.15% |
| 2016 Q2 | 72.31 Million USD | 0.15% |
| 2016 Q3 | 72.43 Million USD | 0.15% |
| 2016 Q4 | 23.64 Million USD | -67.36% |
| 2015 Q4 | 72.09 Million USD | 6.38% |
| 2015 Q3 | 67.77 Million USD | 0.15% |
| 2015 FY | 72.09 Million USD | 6.87% |
| 2015 Q1 | 67.56 Million USD | 0.15% |
| 2015 Q2 | 67.67 Million USD | 0.15% |
| 2014 FY | 67.46 Million USD | 0.62% |
| 2014 Q1 | 67.15 Million USD | 0.15% |
| 2014 Q4 | 67.46 Million USD | 0.16% |
| 2014 Q3 | 67.35 Million USD | 0.15% |
| 2014 Q2 | 67.25 Million USD | 0.15% |
| 2013 Q4 | 67.04 Million USD | 0.16% |
| 2013 Q3 | 66.94 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 67.04 Million USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q2 | 4.68 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | 4.45 Million USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1999 Q1 | 40.83 Thousand USD | 0.0% |
| 1999 Q3 | 36.58 Thousand USD | -10.41% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q2 | 40.83 Thousand USD | 0.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 47.93 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -833.535% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Armata Pharmaceuticals, Inc. | 82.3 Million USD | 94.386% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | -193.957% |
| Azitra, Inc. | 563.69 Thousand USD | -719.774% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -35446.154% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | -124.32% |
| CEL-SCI Corporation | 11.6 Million USD | 60.172% |
| iBio, Inc. | 3.5 Million USD | -31.765% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | -123.237% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | -59.62% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -146.886% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -317.058% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | 14.458% |
| BiomX Inc. | 5.4 Million USD | 14.458% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -2721.433% |
| Scorpius Holdings, Inc. | 12.61 Million USD | 63.364% |
| Theriva Biologics, Inc. | 162 Thousand USD | -2752.469% |